|
Company Profile
Industry Sector: Musculoskeletal Devices;
Biological
drug-eluting synthetic bone grafts and implants
Company Overview: Bonenta is founded upon a
proprietary platform technology for biologic drug development enabling both
safety and effectiveness in the drug-eluting synthetic bone graft
industry. Bonenta’s lead product
candidate enhances bone healing, and our intellectual property could become
the gold standard of the bone graft industry.
Target Market(s): Synthetic bone grafts are a sector
of the multi-billion dollar wound healing market. Craniofacial implants and bone grafting represent over a 5
billion dollar segment of this market, and is growing briskly at 15%
(Kalorama), while the market for orthopedic implants and bone grafting is
much larger. Bonenta will
initially target craniofacial bone repair and is preparing for Phase I
clinical trials.
|
|
|